Alzheimer Disease

Alzheimer patients may require less caregiver time when treated with Reminyl

Published in Health and Medicine Week, November 24th, 2003

Caregivers of patients with mild to moderate Alzheimer disease being treated with the drug Reminyl (galantamine HBr) spend less time providing care each day than do those caring for a patient taking a placebo, according to a newly published study.

Patients treated with Reminyl may also be unsupervised for more time per day compared with those taking placebo. The study appears in the peer-reviewed International Journal of Geriatric Psychiatry.

"Galantamine has been shown to have positive effects on cognition, function, global response and behavior in patients with mild-to-moderate Alzheimer disease," according to Mary Sano, PhD, director of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2003-11-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry